The drug--drug interaction between proton pump inhibitors and clopidogrel

Lau, Wei C.
March 2009
CMAJ: Canadian Medical Association Journal;3/31/2009, Vol. 180 Issue 7, p699
Academic Journal
In this article the authors discuss the study to examine a cytochrome P450 2C19-dependent drug-drug interaction between proton pump inhibitors and clopidogrel. They mention that the study was adapted for the imbalances in covariates such as cardiovascular comorbidities and evidence-based cardiovascular medications. However, they note that the study lack of data on patient compliance with antiplatelet therapy and did not account for ethnicity.


Related Articles

  • Interaction between clopidogrel and proton pump inhibitors: A clinical overview. Nagavi, Jinesh B.; Gurupadayya, B. M. // International Journal of Pharmacy;Jul2014, Vol. 4 Issue 3, p141 

    Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active metabolite. The clinical significance of this drug interaction is unknown. Over recent years there has been much debate about whether some or all proton pump inhibitors might reduce the effectiveness of...

  • A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Juurlink, David N.; Gomes, Tara; Ko, Dennis T.; Szmitko, Paul E.; Austin, Peter C.; Tu, Jack V.; Henry, David A.; Kopp, Alex; Mamdani, Muhammad M. // CMAJ: Canadian Medical Association Journal;3/31/2009, Vol. 180 Issue 7, p713 

    Background: Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active metabolite. The clinical significance of this drug interaction is unknown. Methods: We conducted a population-based nested case-control study among patients aged 66 years or older who commenced...

  • Potentially Fatal Interaction between Diltiazem and Statins. Gladding, Patrick; Pilmore, Helen; Edwards, Colin // Annals of Internal Medicine;4/20/2004, Vol. 140 Issue 8, pE-676 

    Discusses the results of a fatal interaction between diltiazem and statins. Description of the interaction between diltiazem and statins, atorvastatin and simvastatin, as the objective; Details of three case reports of patients taking this combination and complications leading to death;...

  • An insight into the Interaction between Clopidogrel and Proton Pump Inhibitors. Shah, Bhavik S.; Parmar, Sanjay A.; Mahajan, Shailaja; Mehta, Anita A. // Current Drug Metabolism;Feb2012, Vol. 13 Issue 2, p225 

    Platelet activation and aggregation have been established as pivotal elements in the pathogenesis of atherosclerotic and ischemic diseases, including acute coronary syndromes. The difficulty of achieving optimal platelet inhibition remains a major constraint following dual-antiplatelet therapy,...

  • Influence of Helicobacter pylori Eradication Therapy on 13C Aminopyrine Breath Test: Comparison Among Omeprazole-, Lansoprazole-, or Pantoprazole-Containing Regimens. Giannini, Edoardo; Romagnoli, Paola; Fasoli, Alberto; Chiarbonello, Bruno; Malfatti, Federica; Botta, Federica; Risso, Domenico; Lantieri, Pasquale B.; Savarino, Vincenzo; Testa, Roberto // American Journal of Gastroenterology;Oct2000, Vol. 95 Issue 10, p2762 

    OBJECTIVE: Proton pump inhibitors and antimicrobial agents are widely used to eradicate Helicobacter pylori (H. pylori) infection. In the general population the prevalence of infection and of polypharmacy increases the possibility of drug-drug interactions during H. pylori...

  • Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve. Niioka, Takenori; Uno, Tsukasa; Yasui-Furukori, Norio; Shimizu, Mikiko; Sugawara, Kazunobu; Tateishi, Tomonori // European Journal of Clinical Pharmacology;Oct2006, Vol. 62 Issue 10, p855 

    The purpose of this study is to evaluate whether a simple formula using limited blood samples can predict the area under the plasma rabeprazole concentration-time curve (AUC) in co-administration with CYP inhibitors. A randomized double-blind placebo-controlled crossover study design in three...

  • Genetic and environmental risk factors for oral anticoagulant overdose. Verstuyft, C.; Robert, A.; Morin, S.; Loriot, M. A.; Flahault, A.; Beaune, P.; Funck-Brentano, C.; Jaillon, P.; Becquemont, L. // European Journal of Clinical Pharmacology;Mar2003, Vol. 58 Issue 11, p739 

    Background. Cytochrome P450 2C9 (CYP2C9) allelic variant carriers have been shown to experience hyper-responsiveness to small doses of oral anticoagulants (OAs) (warfarin or acenocoumarol) and a higher bleeding rate. Objectives. To determine the relative frequencies of different risk factors for...

  • Safety Aspects of Statins: Which Factors Create the Adverse Effects of Statins. Makino, Hisashi; Harada-Shiba, Mariko // Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Jun2008, Vol. 8 Issue 2, p172 

    Statins have been shown to have beneficial effects on myocardial infarction, revascularization, stroke, and cardiovascular mortality in numerous clinical trials. Seven kinds of statins are available today and have different characteristics in their efficacy of LDL-lowering, their metabolism and...

  • Avoid even normal consumption of grapefruit juice if potential interaction with oral cardiovascular drugs. Adis International Limited // Drugs & Therapy Perspectives;Sep2005, Vol. 21 Issue 9, p21 

    Examines the interaction between grapefruit juice and cardiovascular drugs. Inhibition of the cytochrome P450 3A4 enzyme; Factors affecting the magnitude of interaction between grapefruit juice and drugs; List of oral cardiovascular drugs that have been studied or may meet criteria for a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics